# A Gene Therapy Trial to Evaluate the Safety and Efficacy of RP-L201 in Subjects With Leukocyte Adhesion Deficiency-I

> **NCT03825783** · PHASE1 · WITHDRAWN · sponsor: **Rocket Pharmaceuticals Inc.**

## Conditions studied

- Leukocyte Adhesion Defect - Type I

## Interventions

- **BIOLOGICAL:** RP-L201

## Key facts

- **NCT ID:** NCT03825783
- **Lead sponsor:** Rocket Pharmaceuticals Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2019-04-15
- **Primary completion:** 2021-10
- **Final completion:** 2021-10
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Patients were enrolled under global Phase 1/2 protocol RP-L201-0318.
- **Last updated:** 2021-12-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03825783

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03825783, "A Gene Therapy Trial to Evaluate the Safety and Efficacy of RP-L201 in Subjects With Leukocyte Adhesion Deficiency-I". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03825783. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*